Examples of using CRISPR/Cas9 include models of EGFR exon 20 mutations to study the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib [17], or ablation of Aurora-B that re-sensitizes resistant lung cancer cell lines to cisplatin [18]. This evidence concerns the gene EGFR and lung carcinoma.